Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Core Insights - Zelluna has announced a clinical partnership with Medpace to support the first clinical trial of its lead product candidate, ZI-MA4-1, which is an allogeneic T Cell Receptor-based Natural Killer (TCR-NK) cell therapy for solid cancers [1][3][9] Company Overview - Zelluna ASA is pioneering TCR-NK cell therapies targeting solid cancers, with ZI-MA4-1 being the world's first MAGE-A4 targeting TCR-NK therapy [7] - The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker ZLNA [7] Clinical Development - The partnership with Medpace is a strategic move for Zelluna as it transitions from preclinical to clinical stage, providing access to necessary infrastructure and expertise for executing a complex cell therapy trial [3][6] - The planned Phase 1 study will assess safety, tolerability, and early signs of clinical activity in patients with advanced solid cancers, including lung cancer, ovarian cancer, head and neck cancer, and sarcomas [5][9] - Initial clinical data from the study is expected to emerge from mid-2026, marking the first clinical validation of Zelluna's proprietary TCR-NK platform [5][9] Medpace's Role - Medpace will provide comprehensive clinical development services, including clinical operations, trial management, regulatory support, data management, and pharmacovigilance [3][9] - Medpace has a strong track record in early-phase development and oncology, which aligns with Zelluna's goals for the ZI-MA4-1 study [6][10]